From our results, we saw that 4E-BP1 and eIF4G were significantly altered in CLL cells treated with NVP-BEZ235 when compared to Ibrutinib and Idelalisib, two drugs that target upstream BCR-related effectors involved in PI3K/AKT activation [20, 21]. This evidence concerns the gene EIF4EBP1 and B-cell chronic lymphocytic leukemia.